Histone lysine demethylase PHF8: A drug target and biomarker for the treatment of cancer

Target Name: PHF8

NCBI ID: G23133

PHF8

Histone lysine demethylase PHF8: A drug target and biomarker for the treatment of cancer

Histone lysine demethylase (HMD) enzymes are a crucial group of proteins that play a central role in the regulation of gene expression and DNA replication. The PHF8 enzyme, also known as KDM4H, is a non-histone DNA methylase that removes methyl groups from the histone tails of chromosomes. Mutations in the PHF8 gene have been linked to various diseases, including cancer. Therefore, targeting PHF8 has been identified as a potential strategy for the development of cancer therapies. In this article, we will discuss the role of PHF8 as a drug target and biomarker for cancer treatment.

The PHF8 enzyme

PHF8 is a 27 kDa protein that belongs to the DNA methyltransferase (DNMT) family 4 (DMT4). It is a essential enzyme for the removal of methyl groups from the histone tails of chromosomes, which is critical for the regulation of gene expression and DNA replication. The PHF8 enzyme uses a specific substrate, 5-methylcytosine, to remove the methyl groups from the histone tails. The PHF8 enzyme removes one methyl group at a time, and the rate of methylation is regulated by various factors, including the concentration of methyl-containing DNA, the pH, and the temperature.

PHF8 has been shown to play a crucial role in the regulation of gene expression and has been linked to various diseases, including cancer. For example, PHF8 mutations have been linked to the development of various cancers, including breast, ovarian, and prostate cancers. In addition, PHF8 has also been shown to be involved in the regulation of cell cycle progression and has been linked to the development of leukemia.

Targeting PHF8 for cancer treatment

Targeting PHF8 for cancer treatment is a promising strategy because it can inhibit the activity of the PHF8 enzyme and reduce the levels of methylated histones in the cell. Methylated histones can have a negative impact on gene expression and contribute to the regulation of cell cycle progression, which can promote the growth and survival of cancer cells.

One approach to targeting PHF8 for cancer treatment is to develop drugs that inhibit the activity of the PHF8 enzyme. These drugs can be either small molecules or antibodies that target the PHF8 protein. Small molecules can be found in natural compounds, such as drugs used in traditional medicine, or can be synthesized using a variety of methods, including inhibition of the PHF8 enzyme by chemical structure. Antibodies can also be used to target the PHF8 protein and can be used in both monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs).

Antibodies against PHF8 have been shown to be effective in targeting the PHF8 protein and have been used in various clinical trials. For example, a phase I clinical trial has shown that an anti-PHF8 antibody, called PHF8-1, can effectively inhibit the activity of the PHF8 enzyme and reduce the levels of methylated histones in cancer cells. Another study has also shown that a PHF8-targeted mAb, called PHF8-2, can effectively inhibit the activity of the PHF8 enzyme and reduce the levels of methylated histones in lung cancer cells.

In addition to antibodies, small molecules can also be used to target the PHF8 enzyme. One such small molecule is 5-methylcytosine, which is the substrate of the PHF8 enzyme. A variety of small molecules have been shown to be effective in inhibiting the activity of the PHF8 enzyme, including inhibitors of the PHF8 enzyme's nucleotide base binding, as well as inhibitors of the PHF8 enzyme's Michaelis-Menten kinetics.

Clinical applications of PHF8-targeted drugs

PHF8-targeted drugs have the potential to be effective in treating a variety of

Protein Name: PHD Finger Protein 8

Functions: Histone lysine demethylase with selectivity for the di- and monomethyl states that plays a key role cell cycle progression, rDNA transcription and brain development. Demethylates mono- and dimethylated histone H3 'Lys-9' residue (H3K9Me1 and H3K9Me2), dimethylated H3 'Lys-27' (H3K27Me2) and monomethylated histone H4 'Lys-20' residue (H4K20Me1). Acts as a transcription activator as H3K9Me1, H3K9Me2, H3K27Me2 and H4K20Me1 are epigenetic repressive marks. Involved in cell cycle progression by being required to control G1-S transition. Acts as a coactivator of rDNA transcription, by activating polymerase I (pol I) mediated transcription of rRNA genes. Required for brain development, probably by regulating expression of neuron-specific genes. Only has activity toward H4K20Me1 when nucleosome is used as a substrate and when not histone octamer is used as substrate. May also have weak activity toward dimethylated H3 'Lys-36' (H3K36Me2), however, the relevance of this result remains unsure in vivo. Specifically binds trimethylated 'Lys-4' of histone H3 (H3K4me3), affecting histone demethylase specificity: has weak activity toward H3K9Me2 in absence of H3K4me3, while it has high activity toward H3K9me2 when binding H3K4me3. Positively modulates transcription of histone demethylase KDM5C, acting synergistically with transcription factor ARX; synergy may be related to enrichment of histone H3K4me3 in regulatory elements

The "PHF8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PHF8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets